← Back to Search

Understanding Episodic Memory in Epilepsy

N/A
Waitlist Available
Led By Ueli Rutishauser, PhD
Research Sponsored by Cedars-Sinai Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥13
Intractable epilepsy, undergoing invasive monitoring
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Summary

This trial involves monitoring brain cell activity and using small electrical pulses to understand how memories are formed and used. It targets patients with drug-resistant epilepsy because their treatment allows direct study of brain activity. By observing and stimulating brain cells, researchers aim to learn more about memory and decision-making.

Who is the study for?
This trial is for individuals aged 13 or older with intractable epilepsy who are already undergoing invasive monitoring. Participants should have an IQ over 70 and be able to understand and perform tasks on a computer by pressing buttons. Those unable to complete the tasks due to cognitive, psychological limits, or pain cannot join.
What is being tested?
The study aims to understand how humans learn, recall information, and make decisions using various devices: Cedrus response pad for inputs; Adtech micro-electrodes, Neurolynx system for brain activity recording; Blackrock stimulator possibly for stimulating specific brain areas during tests.
What are the potential side effects?
Since this trial involves non-drug interventions focused on monitoring and testing brain function rather than treatment side effects may include discomfort from wearing the equipment or potential risks associated with invasive monitoring as determined by clinicians.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 13 years old or older.
Select...
I have severe epilepsy and am undergoing special monitoring.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Decision Making (Firing Rates)
Decision Making (Power)
Decision Making (Timing)
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Behavioral TestingExperimental Treatment1 Intervention
Behavioral and Neuronal Recordings

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Epilepsy treatments aim to modulate neuronal activity to prevent seizures. Transcranial Magnetic Stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain, potentially reducing seizure frequency by altering cortical excitability. This noninvasive method is particularly useful for patients who do not respond well to medication. Other common treatments include antiepileptic drugs (AEDs) that stabilize neuronal membranes and reduce excitability, and surgical interventions that remove or isolate the seizure focus. Understanding these mechanisms is crucial for epilepsy patients as it helps tailor treatment plans to individual needs, improving outcomes and quality of life.

Find a Location

Who is running the clinical trial?

California Institute of TechnologyOTHER
15 Previous Clinical Trials
3,049 Total Patients Enrolled
1 Trials studying Epilepsy
50 Patients Enrolled for Epilepsy
Cedars-Sinai Medical CenterLead Sponsor
509 Previous Clinical Trials
165,713 Total Patients Enrolled
1 Trials studying Epilepsy
50 Patients Enrolled for Epilepsy
Johns Hopkins UniversityOTHER
2,315 Previous Clinical Trials
14,872,523 Total Patients Enrolled
19 Trials studying Epilepsy
1,289 Patients Enrolled for Epilepsy

Media Library

Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system; Blackrock Cerestim stimulator Clinical Trial Eligibility Overview. Trial Name: NCT04500119 — N/A
Epilepsy Research Study Groups: Behavioral Testing
Epilepsy Clinical Trial 2023: Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system; Blackrock Cerestim stimulator Highlights & Side Effects. Trial Name: NCT04500119 — N/A
Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system; Blackrock Cerestim stimulator 2023 Treatment Timeline for Medical Study. Trial Name: NCT04500119 — N/A
~31 spots leftby Aug 2025